Buy AROMASIN 25MG (EXEMESTANE) Online

Description

Chemical name: (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
Formula: C20H24O2

Introduction

AROMASIN 25MG, manufactured by Pfizer, is a medication containing exemestane as its active substance. It belongs to the class of medications known as steroidal aromatase inhibitors and is primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. This description provides an overview of AROMASIN 25MG, its characteristics, clinical applications, and considerations.

Characteristics

1. Active Substance: AROMASIN 25MG contains exemestane, a steroidal aromatase inhibitor that works by blocking the enzyme aromatase, which is responsible for converting androgens into estrogens in peripheral tissues. By inhibiting estrogen production, exemestane helps suppress estrogen-dependent tumor growth in hormone receptor-positive breast cancer.
2. Formulation: AROMASIN 25MG is available in the form of tablets, with each tablet containing a specific dosage of exemestane (25 milligrams). The tablets are formulated for oral administration and are designed to provide a precise and standardized dosage of the active ingredient.

Clinical Applications

1. Breast Cancer Treatment: AROMASIN 25MG is indicated for the adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women who have completed two to three years of tamoxifen therapy. It is also used for the treatment of advanced breast cancer (metastatic breast cancer) in postmenopausal women who have progressed following antiestrogen therapy.

Considerations

1. Dosage and Administration: The recommended dosage of AROMASIN 25MG is one tablet (25 milligrams) taken orally once daily, preferably after a meal. Treatment duration may vary depending on factors such as the stage of breast cancer, treatment response, and individual patient factors. Healthcare providers may adjust the dosage or duration of therapy based on clinical assessments and tumor monitoring.
2. Adverse Effects: Common adverse effects associated with AROMASIN 25MG may include hot flashes, fatigue, headache, musculoskeletal pain, insomnia, and nausea. These side effects are usually mild to moderate in severity and transient in nature. Patients should report any persistent or bothersome symptoms to their healthcare provider.
3. Bone Health: Long-term use of aromatase inhibitors like AROMASIN 25MG may increase the risk of osteoporosis and fractures due to estrogen depletion. Healthcare providers may recommend measures to promote bone health, such as calcium and vitamin D supplementation, weight-bearing exercises, and bone density monitoring.
4. Hormone Receptor Status: AROMASIN 25MG is specifically indicated for the treatment of hormone receptor-positive breast cancer. Before initiating treatment, patients may undergo testing to determine the hormone receptor status of their tumor to ensure appropriate selection of therapy.
5. Contraindications: AROMASIN 25MG is contraindicated in individuals with a known hypersensitivity to exemestane or any of its components. It should not be used in premenopausal women, as it may cause ovarian suppression and infertility. AROMASIN 25MG should be used with caution in patients with hepatic impairment or a history of osteoporosis.

Conclusion

AROMASIN 25MG, containing exemestane as its active substance, is a valuable medication for the treatment of hormone receptor-positive breast cancer in postmenopausal women. By inhibiting estrogen production, AROMASIN 25MG helps suppress tumor growth and improve treatment outcomes. However, its use requires careful consideration of dosage, duration of therapy, and potential risks, and should be guided by a qualified healthcare provider to ensure safe and effective treatment outcomes. As with any medication, consultation with a healthcare provider is essential to determine the appropriate use of AROMASIN 25MG and minimize potential risks.